CD8A and cancer: The advent of novel cancer treatments, such as immune checkpoint blockers, neoantigen vaccines, chimeric antigen receptor T (CAR-T) cell therapy and T-cell receptor T (TCR-T) cell therapy, points to that CD8+ T cell-based immunotherapy has gained dramatic breakthroughs.